Inventor
NAGY MARK A
US26 patents
⚠️ This page may combine multiple inventors who share the name “NAGY MARK A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
12 patentsUS10357489B2Jul 23, 2019
Antiproliferative compounds and methods of use thereof
CELGENE CORP20 citations92
US11149007B2Oct 19, 2021
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP14 citations84
US11325889B2May 10, 2022
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP11 citations83
US11185543B2Nov 30, 2021
Antiproliferative compounds and methods of use thereof
CELGENE CORP5 citations82
US11873283B2Jan 16, 2024
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP2 citations71
US12404241B2Sep 2, 2025
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11945804B2Apr 2, 2024
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11358952B2Jun 14, 2022
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP1 citations60
US12029738B2Jul 9, 2024
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations59
US12486281B2Dec 2, 2025
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations56
US11306101B2Apr 19, 2022
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations56
US10675281B2Jun 9, 2020
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations51
SIGNAL PHARM LLC
8 patentsUS9701643B2Jul 11, 2017
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC19 citations91
US10919865B2Feb 16, 2021
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC3 citations83
US10266500B2Apr 23, 2019
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC5 citations83
US10040770B2Aug 7, 2018
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC7 citations83
US11325890B2May 10, 2022
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC2 citations72
US11241430B2Feb 8, 2022
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC0 citations62
US12129237B2Oct 29, 2024
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC0 citations61
US10517873B2Dec 31, 2019
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC0 citations50
SIGNAL PHARMACEUTICAL LLC
3 patentsUS9428509B2Aug 30, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9346812B2May 24, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9795607B2Oct 24, 2017
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC0 citations49